Upregulation of E-cadherin and TGF-β, and downregulation of N-cadherin and ICAM-1, inhibit tumor growth by suppressing EMT and reduce the invasiveness and metastatic potential of PTC by activating the MAPK, PI3K/AKT, and p16/Rb pathways. The gene discussed is AKT1; the disease is neoplasm.